b-cells

Documents about b-cells

• A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy#992506ClinicalTrials.gov
• T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia#851126ClinicalTrials.gov
• Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab#807524ClinicalTrials.gov
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy#860111ClinicalTrials.gov
• Humoral immunity in HIV-1 post-treatment controllers#354035HAL (France)
• Hypoxia Independently Induces AID Expression in CH12 B Cells#388221HAL (France)
• Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL#884515ClinicalTrials.gov
• TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia#887058ClinicalTrials.gov
• SAP loss limits anti-insulin atypical B cell activation and pro-inflammatory CD8 T cells despite preserved Tfh responses to protect against type 1 diabetes#623298bioRxiv / medRxiv
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma#181754ClinicalTrials.gov
• Extracellular vesicles from wild-type Epstein–Barr virus–transformed B-cells export host DNA and the viral lncRNA EBER1#149878Unpaywall
• Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome#849171ClinicalTrials.gov
• A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia#896249ClinicalTrials.gov
• Rituximab to Treat Neuropathy With Anti-MAG Antibodies#968894ClinicalTrials.gov
• CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies#858972ClinicalTrials.gov
• Inflammation‐Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity#471879HAL (France)
• Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL#875766ClinicalTrials.gov
• <b>Stem Cell Applications in Regeneration of Nasal Epithelium: A Phase I/II Open-Label Trial of Autologous Olfactory Epithelial Basal Cell Transplantation for Post-Viral Olfactory Dysfunction</b>#261759Figshare
• Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters#235407IRIS
• Activity of CD37-ADCs in rituximab-resistant and CD20-deficient Raji lymphoma models#396761RepOD Dataverse OAI Archive
• BCL6 in T cells promotes type 1 diabetes by redirecting fates of insulin-autoreactive B lymphocytes#485224Europe PMC
• Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies#966179ClinicalTrials.gov
• Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia#968677ClinicalTrials.gov
• The case for an Epstein-Barr virus vaccine: Lessons from its link to systemic lupus erythematosus#120197Europe PMC
• A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas#300255ClinicalTrials.gov
• Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d’Enregistrement et Suivi des patients traités par CAR-T cells) registry#239043HAL (France)
• Long-term Follow-up Study of Patients Receiving CAR-T Cells#918878ClinicalTrials.gov
• The prognostic impact of monocyte fluorescence, immunosuppressive monocytes and peripheral blood immune cell numbers in HIV-associated Diffuse Large B-cell Lymphoma#279057WIReDSpace
• Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis#901469ClinicalTrials.gov
• Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection#190637UNSWorks Repository
• Immunophenotypic changes in pediatric patients with recurrent infections following inosine acedoben dimepranol therapy: a case-based analysis#336847ARPHA OAI-PMH Endpoint
• A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)#833406ClinicalTrials.gov
• An amino acid insertion in the PHI loop of the VP2 capsid protein of serotype 1 infectious bursal disease virus deeply modifies its antigenicity and abrogates its propagation into B cells.#218865NCBI PubMed Central
• Dynamic modeling and analysis of the cross-talk between Insulin/AKT and MAPK/ERK signaling pathways#934582Koc University Digital Collections
• "Bioink in Dental Practice": Current Applications, Challenges, and Future Trajectories- A Review.#299588Zenodo (CERN)
• Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)#883085ClinicalTrials.gov
• Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the "safe harbor" AAVS1 locus#646713Repisalud
• Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected Volunteers#825155ClinicalTrials.gov
• Hysteroscopy and CD138+ Plasma Cell Density in Chronic Endometritis#879324ClinicalTrials.gov
• Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR#467597ClinicalTrials.gov
• Extensive peripheral immunoglobulin repertoire analyses in people with multiple sclerosis reveal disease-specific signatures and distinct treatment effects of disease modifying drugs#123282Europe PMC
• T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas#217037ClinicalTrials.gov
• Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation#801495ClinicalTrials.gov
• Functions Of Bruton's Tyrosine Kinase In Mast And B Cells#412854OpenCitations
• FT576 in Subjects With Multiple Myeloma#902434ClinicalTrials.gov
• γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)#1031670ClinicalTrials.gov
• Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20#893275ClinicalTrials.gov
• Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma#899860ClinicalTrials.gov
• 2-(5,6-Difluoro-3-oxo-2,3-dihydro-1H-inden-1-ylidene)-malononitrile and Naphtho[2,3-b]thiophene Diimide End-Capped Porphyrin Derivatives as Panchromatic Light-Harvesting Absorbers and Non-Fullerene Acceptors in Organic Solar Cells.#1001185NCBI PubMed Central
• Dual targeting of solid tumors using cytokine-induced killer cells modified with a CAR anti-tenascin C and a secretable EGFRxCD3 bispecific antibody#202774IRIS